Maqola

MULTIMODALITY TREATMENT OF GLIOBLASTOMA PATIENTS USING DIFFERENT TEMOZOLOMIDE REGIMENS IN POSTOPERATIVE CHEMORADIOTHERAPY

Edvard A. ZhavridРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваPavel D. DemeshkoРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваN.A. ArtemovaРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. АлександроваV. SinaykoРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова

2017en

Ochiq kirishOlmos

Litsenziya: cc-by-nc-nd

ABI

Annotatsiya

The outcomes of multimodality treatment of 227 glioblastoma (grade IV) patients were evaluated in relation to the postoperative chemoradiotherapy (ChRT) regimen. No statistically significant differences were found in groups with conventional ChRT (temozolomide 75 mg/m2 per os 1 hour before the radiation treatment during the whole course of radiotherapy, n=111) and modified ChRT (temozolomide 75 mg/m2 per os 5 days a week 1 hour before the radiation treatment in the first and last two weeks of radiotherapy, n=116), the median overall survival being 16 months and 16 months respectively (P=0,889). The Cox proportional hazards model demonstrated that the postoperative ChRT regimen was not a prognostic factor affecting patient survival.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.37469/0507-3758-2017-63-6-915-919

Iqtiboslar va manbalar

0 ta iqtibos2 ta foydalanilgan manba